Amalgamated Bank Cara Therapeutics, Inc. Transaction History

Amalgamated Bank

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$0.52 - $1.05 $1,361 - $2,748	-2,618 Reduced 63.13%	1,529 $1,000
Q4 2023 Feb 06, 2024	SELL	$0.6 - $1.65 $273 - $750	-455 Reduced 9.89%	4,147 $3,000
Q2 2023 Aug 11, 2023	SELL	$2.83 - $4.94 $45,311 - $79,094	-16,011 Reduced 77.67%	4,602 $13,000
Q1 2023 May 02, 2023	BUY	$4.89 - $12.27 $1,569 - $3,938	321 Added 1.58%	20,613 $101,000
Q3 2022 Nov 09, 2022	BUY	$8.24 - $12.56 $5,957 - $9,080	723 Added 3.69%	20,292 $190,000
Q2 2022 Aug 15, 2022	BUY	$7.45 - $13.84 $3,732 - $6,933	501 Added 2.63%	19,569 $179,000
Q1 2022 Jun 30, 2022	SELL	$9.94 - $12.65 $11,510 - $14,648	-1,158 Reduced 5.73%	19,068 $232,000
Q4 2021 Feb 15, 2022	SELL	$11.99 - $18.14 $9,663 - $14,620	-806 Reduced 3.83%	20,226 $246,000
Q3 2021 Oct 29, 2021	SELL	$11.55 - $16.06 $4,308 - $5,990	-373 Reduced 1.74%	21,032 $325,000
Q2 2021 Aug 16, 2021	BUY	$12.38 - $29.19 $264,993 - $624,811	21,405 New	21,405 $305,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $14.5M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.